Lung Cancer — 5-Minute Journal Club Issue 4 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates

About this episode

Dr Aaron Lisberg discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.

Dr Aaron Lisberg from the University of California, Los Angeles, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer.  CME information and select publications here .

People in this episode

Host: Dr. Neil Love

Guest: Dr Aaron Lisberg

Topics covered

• lung cancer
• antibody-drug conjugates
• TROP2
• non-small cell lung cancer
• medical research

Keywords

• lung cancer
• TROP2
• antibody-drug conjugates
• non-small cell lung cancer
• CME information

Mentioned in this episode

Organizations: University of California, Los Angeles

Products: TROP2-directed antibody-drug conjugates

Places: non-small cell lung cancer

More episodes of Lung Cancer Update

• Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances · June 9, 2026 · 59 min
• EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances · April 27, 2026 · 57 min
• Lung Cancer — 5-Minute Journal Club with Dr Natalie Vokes: Current and Future Role of Tumor-Informed Circulating Tumor DNA Assays · April 17, 2026 · 27 min
• Extensive-Stage Small Cell Lung Cancer — Current Patterns of Care with First-Line and Maintenance Therapy · February 27, 2026 · 60 min
• Extensive-Stage Small Cell Lung Cancer — What Clinicians Want to Know About First-Line and Maintenance Therapy · December 17, 2025 · 58 min
• Lung Cancer — Proceedings from a Symposium Held in Partnership with the American Oncology Network · December 12, 2025 · 1h 43m